
Deobiosciences
Early-stage, virtual life sciences company.
Date | Investors | Amount | Round |
---|---|---|---|
* | $790k Valuation: $15.6m | Seed | |
Total Funding | 000k |
Related Content
Deo BioSciences is a pioneering biotech company focused on transformative research in global health. Operating from suburban Atlanta, GA, the company leverages a virtual business model to collaborate with leading scientists and institutions worldwide, including Cornell University. Deo BioSciences aims to develop groundbreaking molecules, such as DBX 31, which have significant potential benefits for both humans and pets. The company serves clients in the healthcare and pharmaceutical sectors, targeting markets that demand innovative and effective health solutions. Deo BioSciences generates revenue through research partnerships, grants, and the commercialization of its proprietary technologies. The firm is committed to using the best technologies and resources to advance its research and development phases, ensuring that its innovative solutions reach those in need.
Keywords: biotech, global health, transformative research, Cornell University, DBX 31, healthcare, pharmaceutical, virtual business model, innovative solutions, proprietary technologies.